Back to resultsThe Role of Dendritic Cells in Hepatitis C Infection
Primary Purpose
Chronic Hepatitis C Infection
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Viraferon-peg and Rebetol
Sponsored by
About this trial
This is an interventional basic science trial for Chronic Hepatitis C Infection
Eligibility Criteria
Inclusion Criteria:
- anti-HCV positive
- HCV RNA positive
Exclusion Criteria:
- contraindications for antiviral treatment
- concurrent chronic viral infections
Sites / Locations
- University College Hospital
Outcomes
Primary Outcome Measures
Basic science research (immunology of hepatitis C)in hepatitis c patients receiving established, standard antiviral treatment (pegylated Interferon+Ribavirin)
Secondary Outcome Measures
Full Information
NCT ID
NCT00723242
First Posted
July 24, 2008
Last Updated
July 24, 2008
Sponsor
University College, London
Collaborators
Schering-Plough
1. Study Identification
Unique Protocol Identification Number
NCT00723242
Brief Title
The Role of Dendritic Cells in Hepatitis C Infection
Study Type
Interventional
2. Study Status
Record Verification Date
July 2008
Overall Recruitment Status
Completed
Study Start Date
April 2002 (undefined)
Primary Completion Date
December 2004 (Actual)
Study Completion Date
December 2004 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University College, London
Collaborators
Schering-Plough
4. Oversight
5. Study Description
Brief Summary
The role of the dendritic cells, the most potent antigen presenting cells, in the establishment of chronic hepatitis C is not established. The study aims to define whether the dendritic cells are affected by the hepatitis C virus and whether that bears an impact on the antiviral immune response they generate. The hypothesis is explored by investigating a group of patients prior to and after the initiation of standard treatment for hepatitis C with pegylated Interferon and Ribavirin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Hepatitis C Infection
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Viraferon-peg and Rebetol
Primary Outcome Measure Information:
Title
Basic science research (immunology of hepatitis C)in hepatitis c patients receiving established, standard antiviral treatment (pegylated Interferon+Ribavirin)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
anti-HCV positive
HCV RNA positive
Exclusion Criteria:
contraindications for antiviral treatment
concurrent chronic viral infections
Facility Information:
Facility Name
University College Hospital
City
London
ZIP/Postal Code
NW1 2BU
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
The Role of Dendritic Cells in Hepatitis C Infection
We'll reach out to this number within 24 hrs